Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany.
Department of Pathology and Pathologic Anatomy, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany.
Clin Cancer Res. 2018 May 15;24(10):2342-2349. doi: 10.1158/1078-0432.CCR-17-3771. Epub 2018 Feb 20.
Molecular lymph node (LN) analysis using quantitative polymerase chain reaction (qPCR) detects LN metastases with higher sensitivity than histopathology. However, the prognostic role of molecular LN status in prostate cancer patients treated with radical prostatectomy (RP) and extended pelvic LN dissection (ePLND) is unclear. To investigate the association of molecular compared with histopathologic LN status with biochemical recurrence. Patients with intermediate and high-risk prostate cancer were prospectively enrolled and underwent RP with ePLND, including the obturator, internal, external, and the common iliac region. LNs ≥3 mm were bisected and examined by standard histopathology and qPCR for Kallikrein3 (KLK3) expression. Biochemical recurrence was defined by confirmed postoperative PSA > 0.2 ng/mL. In 111 patients, 2,411 of 3,173 removed LNs were examined by both methods. Histopathology detected 68 LN metastases in 28 (25%) patients. Molecular analysis confirmed elevated KLK3 expression in 65 histopathologic LN metastases of all 28 pN1 patients (pN1/molN1) and additionally reclassified 224 histopathologic negative LNs and 32 (29%) pN0 patients as LN-positive (pN0/molN1).At a median follow-up of 48 months, 52 (47%) patients developed biochemical recurrence. Median biochemical recurrence-free survival was 9 months [95% confidence interval (CI), 0.0-20.1] in pN1/molN1 patients, 24 months (95% CI, 1.7-46.3) in pN0/molN1 patients and was not reached in pN0/molN0 patients ( < 0.001). On multivariable Cox regression analysis, molecular LN status [HR 4.1 (95% CI, 1.9-8.8), < 0.001] but not histopathologic LN status [HR 1.5 (95% CI, 0.8-3.0), = 0.198] was confirmed as independent predictor of biochemical recurrence. Molecular LN analysis identified pN0 patients with a high risk of biochemical recurrence and provided superior prognostic information in comparison with histopathology alone. .
使用定量聚合酶链反应 (qPCR) 进行分子淋巴结 (LN) 分析比组织病理学具有更高的 LN 转移检测灵敏度。然而,在接受根治性前列腺切除术 (RP) 和广泛盆腔 LN 清扫术 (ePLND) 治疗的前列腺癌患者中,分子 LN 状态的预后作用尚不清楚。本研究旨在探讨分子 LN 状态与组织学 LN 状态相比与生化复发的关系。前瞻性纳入中高危前列腺癌患者,行 RP 联合 ePLND,包括闭孔、内收肌、外收肌和髂总区。LN≥3mm 时,采用标准组织病理学和 Kallikrein3 (KLK3) 表达 qPCR 对半切淋巴结进行检查。生化复发定义为术后 PSA 确证>0.2ng/mL。在 111 例患者中,3173 个切除的 LN 中有 2411 个同时进行了两种方法的检查。组织病理学在 28 例(25%)患者的 68 个 LN 转移中检测到转移。分子分析证实 28 例 pN1 患者(pN1/molN1)的 65 个组织学阳性 LN 转移中均存在 KLK3 表达升高,另外还将 224 个组织学阴性 LN 和 32 例(29%)pN0 患者重新分类为 LN 阳性(pN0/molN1)。中位随访 48 个月时,52 例(47%)患者发生生化复发。pN1/molN1 患者的中位生化无复发生存期为 9 个月[95%置信区间 (CI),0.0-20.1],pN0/molN1 患者为 24 个月(95%CI,1.7-46.3),pN0/molN0 患者未达到(<0.001)。多变量 Cox 回归分析证实,分子 LN 状态[HR 4.1(95%CI,1.9-8.8),<0.001]而不是组织学 LN 状态[HR 1.5(95%CI,0.8-3.0),=0.198]是生化复发的独立预测因素。分子 LN 分析确定了 pN0 患者具有生化复发的高风险,并与单独组织病理学相比提供了更好的预后信息。